Clinical efficacy of a petroleum-derived product (Larimsh) used as compassionate treatment in patients with terminal prostate cancer.
Treatment of a light fraction of petroleum treated by metallic catalysis results in a liquid mixture of low molecular weight compounds named LarimshTM (LR). Acute and chronic topical treatment of mice with LR (85 days with 0.1 to 1 mL/animal) indicated no signs of toxicity other than a non dose-dependent, reversible alopecia appearing by the 4th week of topical application. Alopecia completely reversed 2 weeks after treatment withdrawal. Acute oral LR (0.001 to 1 mL; the lowest doses diluted in corn oil as vehicle) gave an estimated LD50 of 21 g/kg (C.I. 95 %: 10.94-41.2 g/kg. LR density = 0.867 g/mL). The antineoplastic action of LR was observed using combined oral and topical treatments in mice; inoculated with a lymphoid leukemia cell line in ascitic phase (International Registry L5178Y); and in terminal patients with prostate cancer (TPCA)--who agreed to receive LR as a compassionate treatment. The survival time for mice was significantly increased when compared with non-treated inoculated mice (51 +/- 2 versus 38 +/- 2 days, p < 0.05, mean +/- SD, N = 6 per group). In 15 patients, LR treatment for 5.5 months (C.I. 95 %: 2.9 to 8.0 months) significantly increased the expected survival time diagnosed to TPCA by their treating physicians (C.I. 95 %: 2.2 to 5.4 versus 12.6 to 41.2 months, p < 0.05) which occurred concomitantly with a significant reduction of blood levels of total prostatic antigen (average 94.5%, range: 67.3 to 99.9%). A theoretical proposal is advanced as a likely explanation of LR actions.
Rodríguez-Pérez
Rafaín
R
Fascimex SA de CV, Mexico City.
García-Montañez
Maritza
M
Lemus-Balcazar
Humberto
H
DeLaRosa Viejo
Marcos
M
Grijalva-Monreal
Jaime
J
Castell-Rodríguez
Andrés E
AE
Ramírez-González
María Dolores
MD
D000818:Animals; D001842:Bone and Bones / Q000000981:diagnostic imaging; D045744:Cell Line, Tumor; D002849:Chromatography, Gas; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008875:Middle Aged; D010166:Palliative Care; D010578:Petroleum / Q000032:analysis*; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000000981:diagnostic imaging / Q000628:therapy*; D011786:Quality Control; D011877:Radionuclide Imaging; D016019:Survival Analysis
D010578:Petroleum; C530400:larimsh; D017430:Prostate-Specific Antigen